Publication:
Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept.

dc.contributor.authorGonzález Astorga, B
dc.contributor.authorSalvà Ballabrera, F
dc.contributor.authorAranda Aguilar, E
dc.contributor.authorÉlez Fernández, E
dc.contributor.authorGarcía-Alfonso, P
dc.contributor.authorGonzález Flores, E
dc.contributor.authorVera García, R
dc.contributor.authorFernández Montes, A
dc.contributor.authorLópez Muñoz, A M
dc.contributor.authorSalud Salvia, A
dc.date.accessioned2023-02-09T10:43:17Z
dc.date.available2023-02-09T10:43:17Z
dc.date.issued2021-02-25
dc.description.abstractColorectal cancer is the second leading cause of cancer-related death worldwide. For metastatic colorectal cancer (mCRC) patients, it is recommended, as first-line treatment, chemotherapy (CT) based on doublet cytotoxic combinations of fluorouracil, leucovorin, and irinotecan (FOLFIRI) and fluorouracil, leucovorin, and oxaliplatin (FOLFOX). In addition to CT, biological (targeted agents) are indicated in the first-line treatment, unless contraindicated. In this context, most of mCRC patients are likely to progress and to change from first line to second line treatment when they develop resistance to first-line treatment options. It is in this second line setting where Aflibercept offers an alternative and effective therapeutic option, thought its specific mechanism of action for different patient's profile: RAS mutant, RAS wild-type (wt), BRAF mutant, potentially resectable and elderly patients. In this paper, a panel of experienced oncologists specialized in the management of mCRC experts have reviewed and selected scientific evidence focused on Aflibercept as an alternative treatment.
dc.identifier.doi10.1007/s12094-021-02568-y
dc.identifier.essn1699-3055
dc.identifier.pmcPMC8238745
dc.identifier.pmid33630242
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238745/pdf
dc.identifier.unpaywallURLhttps://link.springer.com/content/pdf/10.1007/s12094-021-02568-y.pdf
dc.identifier.urihttp://hdl.handle.net/10668/17231
dc.issue.number8
dc.journal.titleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
dc.journal.titleabbreviationClin Transl Oncol
dc.language.isoen
dc.organizationHospital Universitario Reina Sofía
dc.organizationHospital Universitario San Cecilio
dc.organizationHospital Universitario Virgen de las Nieves
dc.organizationHospital Universitario San Cecilio
dc.organizationHospital Universitario Reina Sofía
dc.organizationHospital Universitario San Cecilio
dc.organizationHospital Universitario Virgen de las Nieves
dc.organizationHospital Universitario San Cecilio
dc.page.number1520-1528
dc.pubmedtypeJournal Article
dc.pubmedtypeReview
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectAflibercept
dc.subjectBRAF
dc.subjectColorectal cancer
dc.subjectMetastatic
dc.subjectMutation
dc.subjectPatient profile
dc.subjectPatient selection
dc.subjectRAS
dc.subjectTreatment
dc.subject.meshAge Factors
dc.subject.meshAngiogenesis Inhibitors
dc.subject.meshAntineoplastic Agents, Immunological
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshBevacizumab
dc.subject.meshCamptothecin
dc.subject.meshClinical Trials, Phase III as Topic
dc.subject.meshColorectal Neoplasms
dc.subject.meshDrug Substitution
dc.subject.meshFluorouracil
dc.subject.meshGenes, ras
dc.subject.meshHumans
dc.subject.meshLeucovorin
dc.subject.meshLiver Neoplasms
dc.subject.meshLung Neoplasms
dc.subject.meshMutation
dc.subject.meshNeovascularization, Pathologic
dc.subject.meshOrganoplatinum Compounds
dc.subject.meshProto-Oncogene Proteins B-raf
dc.subject.meshReceptors, Vascular Endothelial Growth Factor
dc.subject.meshRecombinant Fusion Proteins
dc.subject.meshVascular Endothelial Growth Factor A
dc.titlePatient profiles as an aim to optimize selection in the second line setting: the role of aflibercept.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number23
dspace.entity.typePublication
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC8238745.pdf
Size:
511.38 KB
Format:
Adobe Portable Document Format